期刊文献+

血清半乳糖凝集素-3与冠心病患者造影剂肾病的关系研究 被引量:3

The Relationship between Serum Galectin-3 and Contrast-induced Nephropathy in Patients with Coronary Heart Disease
下载PDF
导出
摘要 目的:探究血清半乳糖凝集素-3(Galectin-3)与冠心病患者造影剂肾病(CIN)间的关系。方法:选取2018年4-12月于本院行冠状动脉造影术(CAG)的冠心病患者[包括行经皮冠状动脉介入术(PCI术)者]80例,根据造影后患者是否发生CIN,将其分为CIN组和无CIN组。比较两组年龄、高血压发生情况、胆固醇、低密度脂蛋白、N末端B型脑钠肽前体(NT-proBNP)、造影剂用量、左心室射血分数、血清Galectin-3水平;比较两组造影前后血肌酐(Scr)和肾小球滤过率(eGFR)变化情况;对CIN患者进行多因素Logistic回归分析,筛选其危险因素;分析患者Galectin-3水平与上述各参数间的相关性。结果:CIN组7例(8.75%),无CIN组73例(91.25%);两组年龄和高血压发生率比较,差异均无统计学意义(P>0.05);两组胆固醇、低密度脂蛋白、NT-proBNP、造影剂用量、左心室射血分数、Galectin-3水平比较,差异均有统计学意义(P<0.05);造影后第3天,两组Scr水平均高于造影前,且CIN组Scr水平高于无CIN组,差异均有统计学意义(P<0.05),CIN组eGFR水平均低于造影前及无CIN组(P<0.05),无CIN组造影前后eGFR水平比较,差异无统计学意义(P>0.05);Logistic回归分析显示,左心室射血分数和eGFR是CIN的保护因素(OR<1,P<0.05),而胆固醇、低密度脂蛋白、NT-proBNP、造影剂用量、Scr以及Galectin-3水平均是CIN发生的危险因素(OR>1,P<0.05);Pearson相关性分析结果显示,患者Galectin-3水平与高血压发生情况、左心室射血分数、eGFR均呈负相关(P<0.05),与年龄、胆固醇、低密度脂蛋白、NT-proBNP、造影剂用量、Scr均呈正相关(P<0.05)。结论:Galectin-3水平升高与冠心病患者CIN发生存在着密切关联,可用于CIN的预测和诊断。 Objective:To explore the relationship between serum Galectin-3 and contrast-induced nephropathy(CIN)in patients with coronary heart disease.Method:From April to December 2018,80 patients with coronary heart disease[included those undergoing percutaneous coronary intervention(PCI)]underwent coronary angiography(CAG)in our hospital were selected.The patients were divided into CIN group and non CIN group according to whether CIN occurred after angiography.The age,the incidence of hypertension,cholesterol,low density lipoprotein,N-terminal B-type brain natriuretic peptide precursor(NT-proBNP),the dosage of contrast medium,left ventricular ejection fraction and serum Galectin-3 were compared between the two groups,the changes of serum creatinine(Scr)and glomerular filtration rate(eGFR)before and after contrast were compared between the two groups,the risk factors of CIN patients were screened by multivariate logistic regression analysis,and the correlation between Galectin-3 level and the above parameters was analyzed.Result:There were 7 cases(8.75%)in CIN group and 73 cases(91.25%)in non CIN group.There were no significant differences in age and hypertension between the two groups(P>0.05),there were significant differences in the levels of cholesterol,low density lipoprotein,NT-proBNP,contrast agent dosage,left ventricular ejection fraction and Galectin-3 between the two groups(P<0.05).On the third day after contrast,the Scr levels of the two groups were higher than those of before contrast,and the Scr level of the CIN group was higher than that of the non CIN group,the differences were statistically significant(P<0.05),the eGFR levels of the CIN group were lower than those of before contrast and non CIN group(P<0.05),but there was no significant difference in eGFR between the two groups before and after contrast(P>0.05).Logistic regression analysis showed that left ventricular ejection fraction and eGFR were protective factors of CIN(OR<1,P<0.05),while cholesterol,low density lipoprotein,NT-proBNP,contrast agent dosage,Scr and Galectin-3 were all risk factors of CIN(OR>1,P<0.05).Pearson correlation analysis showed that Galectin-3 level were negatively correlated with hypertension,left ventricular ejection fraction and eGFR(P<0.05),and positively correlated with age,cholesterol,low density lipoprotein,NT-proBNP,contrast agent dosage and Scr(P<0.05).Conclusion:The increase of Galectin-3 level is closely related to the occurrence of CIN in patients with coronary heart disease,which can be used for the prediction and diagnosis of CIN.
作者 徐旺 曾芳 马超 袁文金 XU Wang;ZENG Fang;MA Chao;YUAN Wenjin(People’s Hospital of Ganzhou City,Ganzhou 341000,China)
出处 《中国医学创新》 CAS 2019年第33期44-47,共4页 Medical Innovation of China
基金 赣州市指导性科技计划项目(GZ2018ZSF273)
关键词 半乳糖凝集素 -3 冠心病 造影剂肾病 相关性 Galectin-3 Coronary heart disease Contrast-induced nephropathy Correlation
  • 相关文献

参考文献19

二级参考文献205

  • 1张涛,李自成.冠心病易损斑块的研究进展[J].临床心血管病杂志,2004,20(8):509-512. 被引量:18
  • 2徐红,陈丽萌,李学旺.肾功能不全患者发生造影剂肾病的危险因素和预后[J].中国医学科学院学报,2005,27(2):232-236. 被引量:29
  • 3姜文兵,傅国胜.造影剂肾病预防的研究进展[J].临床荟萃,2006,21(12):897-900. 被引量:23
  • 4Curhan G C. Prevention of contrast nephropathy[J]. JAMA, 2003,289(5) :606-608.
  • 5Mueller C, Buerklc G, Buettner H J, et al Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty[J].Arch Intern Med,2002,162(3):329-336.
  • 6Baker C S, Baker I. R. Prevention of contrast nephropathy after cardiaccatheterization[J].Heart,2001,85(4):361 -362.
  • 7Oupta R, Birnbaum Y, Uretsky B F. The renal patient with coronary artery disease. Current concepts and dilemmas[J]. J Am Coll Cardiol,2004,44(7) :1343-1353.
  • 8Huber W, Jeschke B, Kreymann B, et al. Haemodialysis for the prevention of contrast-induced nephropathy[J]. Invest Radiol, 2002,37(9) :471-481.
  • 9Oliveira D B. Prophylaxis against contrast-induced nephropathy [J]. Lancet,1999,353(9165):1638-1639.
  • 10Nikolsky E, Aymong E D, Dangas G, et al. Radioeontrast nephropathy: identifying the high risk patient and the implications exacerbating renal function [J]. Rev Cardiovase Med,2003,4(1) :7-14.

共引文献138

同被引文献28

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部